艾司洛尔在甲状腺功能亢进合并快速心律失常患者中的应用研究

目的:研究艾司洛尔在甲状腺功能亢进(甲亢)合并快速心律失常患者中应用时控制心室率的有效性和安全性。方法:选择甲亢合并快速心律失常患者73例,其中男41例,女32例,年龄(49.7±15.4)岁,分为艾司洛尔组和西地兰组。艾司洛尔组39例,男22例,女17例,年龄(51.1±13.9)岁;西地兰组34例,男21例,女13例,年龄(47.7±16.1)岁,两组间性别、年龄比较差异无统计学意义。艾司洛尔组给予抗甲亢及对症处理,同时应用艾司洛尔持续静脉注射使心室率控制在100次/min或收缩压下降小于30%,12 h后口服普奈洛尔片。西地兰组给予常规西地兰,口服普萘洛尔片,抗甲亢及对症处理。分别观察两组患者不同时间段的心室率、血压、自觉心慌症状。结果:两组间相关指标在用药后不同时段比较差异有统计学意义(P<0.05),且用药后6 h内差异有统计学意义(P<0.001)。结论:艾司洛尔在甲亢合并快速心律失常患者中能有效控制心室率,减轻患者症状,没有出现低血压或房室传导阻滞等不良事件。艾司洛尔在甲亢合并快速心律失常患者中应用安全有效。

The application of esmolol in patients with hyperthyroidism and rapid arrhythmia

Objective：To study the safety and efficacy of esmolol in control ventricular rate of patients with hyperthyroid- ism and rapid arrhythmia. Methods：In 73 cases of hyperthyroidism with rapid arrhythmia patients,including 41 cases of male, 32 female, mean age （49.7 ± 15.4） years old. Divided into esmolol group and cedilauid group. Esmolol group 39 cases, male 22 cases,female 17 cases,mean age （51.1 ± 13.9） years old;cedilanid group 34 cases,male 21 cases,female 15 cases,mean age （47.7 ± 16.1 ） years old. Between two groups there was no significant difference in gender,age. Esmolol group were given anti hyperthyroidism and symptomatic treatment. At the same time, esmolol continuous intravenous injection of ventricular rate control at 100 beats / min or blood pressure decreased to less than 30% , 12 hours later oral propranolol tablets combined with. Cedilanid group received conventional cedilanid, oral propranolol tablets, anti hyperthyroidism and symptomatic treatment. Two groups of patients were observed at different time in patients with heart rate, blood pressure, consciously flustered symptoms. Results ： Between the two groups were compared after medication related in different periods have significant difference （ P 〈 0.05 ）, and to 6 hours significantly different （P 〈 0.001 ）. Conclusion ：Esmolol can effectively control of rapid ventricular rate in patients with hyperthyroidism and rapid arrhythmia. Esmolol in control ventricular rate of patients with hyperthyroidism and rapid arrhythmia is safety and efficacy.